AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteKobe2602 is an analog of Kobe0065. Both compounds exhibit inhibitory activity toward H-Ras?GTP-c-Raf-1 binding both in vivo and in vitro.
More Information Supplier PageKobe2602 is an analog of Kobe0065. Both compounds exhibit inhibitory activity toward H-Ras?GTP-c-Raf-1 binding both in vivo and in vitro.
More Information Supplier PageKobe2602 is an analog of Kobe0065. Both compounds exhibit inhibitory activity toward H-Ras?GTP-c-Raf-1 binding both in vivo and in vitro.
More Information Supplier PageKPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
More Information Supplier PageKPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
More Information Supplier PageKPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
More Information Supplier PageKPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
More Information Supplier PageKPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
More Information Supplier PageKPT185 is a selective CRM1 inhibitor. KPT-185 significantly inhibits leukemia cell proliferation with IC50 ranging from 100 nM to 500 nM, and induces cell-cycle arrest and apoptosis of AML cell lines and primary AML blasts.
More Information Supplier PageKPT185 is a selective CRM1 inhibitor. KPT-185 significantly inhibits leukemia cell proliferation with IC50 ranging from 100 nM to 500 nM, and induces cell-cycle arrest and apoptosis of AML cell lines and primary AML blasts.
More Information Supplier PageKPT185 is a selective CRM1 inhibitor. KPT-185 significantly inhibits leukemia cell proliferation with IC50 ranging from 100 nM to 500 nM, and induces cell-cycle arrest and apoptosis of AML cell lines and primary AML blasts.
More Information Supplier PageKPT185 is a selective CRM1 inhibitor. KPT-185 significantly inhibits leukemia cell proliferation with IC50 ranging from 100 nM to 500 nM, and induces cell-cycle arrest and apoptosis of AML cell lines and primary AML blasts.
More Information Supplier PageKPT185 is a selective CRM1 inhibitor. KPT-185 significantly inhibits leukemia cell proliferation with IC50 ranging from 100 nM to 500 nM, and induces cell-cycle arrest and apoptosis of AML cell lines and primary AML blasts.
More Information Supplier PageKRCA-0008 is a potent and selective ALK/Ack1 inhibitor with IC50 of 12 nM/4 nM for ALK and Ack1 respectively; displays drug-like properties without hERG liability.
More Information Supplier PageKRCA-0008 is a potent and selective ALK/Ack1 inhibitor with IC50 of 12 nM/4 nM for ALK and Ack1 respectively; displays drug-like properties without hERG liability.
More Information Supplier PageKRCA-0008 is a potent and selective ALK/Ack1 inhibitor with IC50 of 12 nM/4 nM for ALK and Ack1 respectively; displays drug-like properties without hERG liability.
More Information Supplier PageKRN 633 is a cell-permeable, reversible, ATP-competitive VEGFR kinase inhibitor that inhibits PDGFR-?? and c-Kit at higher concentrations only (IC50 = 0.97 ??M and 4.33 ??M, respectively) and inactive towards 17 other kinases (IC50 ??? 10 ??M).
More Information Supplier PageKRN 633 is a cell-permeable, reversible, ATP-competitive VEGFR kinase inhibitor that inhibits PDGFR-?? and c-Kit at higher concentrations only (IC50 = 0.97 ??M and 4.33 ??M, respectively) and inactive towards 17 other kinases (IC50 ??? 10 ??M).
More Information Supplier PageKRN 633 is a cell-permeable, reversible, ATP-competitive VEGFR kinase inhibitor that inhibits PDGFR-?? and c-Kit at higher concentrations only (IC50 = 0.97 ??M and 4.33 ??M, respectively) and inactive towards 17 other kinases (IC50 ??? 10 ??M).
More Information Supplier PageKRN 633 is a cell-permeable, reversible, ATP-competitive VEGFR kinase inhibitor that inhibits PDGFR-?? and c-Kit at higher concentrations only (IC50 = 0.97 ??M and 4.33 ??M, respectively) and inactive towards 17 other kinases (IC50 ??? 10 ??M).
More Information Supplier PageKRN 633 is a cell-permeable, reversible, ATP-competitive VEGFR kinase inhibitor that inhibits PDGFR-?? and c-Kit at higher concentrations only (IC50 = 0.97 ??M and 4.33 ??M, respectively) and inactive towards 17 other kinases (IC50 ??? 10 ??M).
More Information Supplier PageKRX-0402 is a small molecule that was specifically designed to block the DNA repair protein, MGMT. MGMT confers resistance to certain alkylating agents, such as temozolomide and BCNU, that are commonly used to treat brain cancer, melanoma and non-Hodgkin??s lymphoma.
More Information Supplier PageKRX-0402 is a small molecule that was specifically designed to block the DNA repair protein, MGMT. MGMT confers resistance to certain alkylating agents, such as temozolomide and BCNU, that are commonly used to treat brain cancer, melanoma and non-Hodgkin??s lymphoma.
More Information Supplier PageKRX-0402 is a small molecule that was specifically designed to block the DNA repair protein, MGMT. MGMT confers resistance to certain alkylating agents, such as temozolomide and BCNU, that are commonly used to treat brain cancer, melanoma and non-Hodgkin??s lymphoma.
More Information Supplier PageKU0060648 is a potent and selective inhibitor of DNA-dependent protein kinase (DNA-PK), (IC50 = 8.6 nM); with 20-1000 fold selectivity for DNA-PK over other PIKKs and a panel of 60 kinases. KU-0060648 enhances HDR efficiency and attenuates NHEJ frequency.
More Information Supplier PageKU0060648 is a potent and selective inhibitor of DNA-dependent protein kinase (DNA-PK), (IC50 = 8.6 nM); with 20-1000 fold selectivity for DNA-PK over other PIKKs and a panel of 60 kinases. KU-0060648 enhances HDR efficiency and attenuates NHEJ frequency.
More Information Supplier PageKU0060648 is a potent and selective inhibitor of DNA-dependent protein kinase (DNA-PK), (IC50 = 8.6 nM); with 20-1000 fold selectivity for DNA-PK over other PIKKs and a panel of 60 kinases. KU-0060648 enhances HDR efficiency and attenuates NHEJ frequency.
More Information Supplier PageKU0060648 is a potent and selective inhibitor of DNA-dependent protein kinase (DNA-PK), (IC50 = 8.6 nM); with 20-1000 fold selectivity for DNA-PK over other PIKKs and a panel of 60 kinases. KU-0060648 enhances HDR efficiency and attenuates NHEJ frequency.
More Information Supplier PageKU-0063794 is a selective inhibitor of mammalian target of rapamycin (mTOR) (IC50 ~10 nM for mTORC1 and mTORC2 respectively).
More Information Supplier PageKU-0063794 is a selective inhibitor of mammalian target of rapamycin (mTOR) (IC50 ~10 nM for mTORC1 and mTORC2 respectively).
More Information Supplier PageKU-0063794 is a selective inhibitor of mammalian target of rapamycin (mTOR) (IC50 ~10 nM for mTORC1 and mTORC2 respectively).
More Information Supplier PageKU-0063794 is a selective inhibitor of mammalian target of rapamycin (mTOR) (IC50 ~10 nM for mTORC1 and mTORC2 respectively).
More Information Supplier PageKU-0063794 is a selective inhibitor of mammalian target of rapamycin (mTOR) (IC50 ~10 nM for mTORC1 and mTORC2 respectively).
More Information Supplier PageKU-55933 is an ATM inhibitor by suppressing cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt.
More Information Supplier PageKU-55933 is an ATM inhibitor by suppressing cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt.
More Information Supplier PageKU-55933 is an ATM inhibitor by suppressing cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt.
More Information Supplier PageKU-55933 is an ATM inhibitor by suppressing cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt.
More Information Supplier PageKU-55933 is an ATM inhibitor by suppressing cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt.
More Information Supplier PageKU14R is an antagonist of the pancreatic ??-cell atypical imidazoline binding site (putative I3 receptor). KU14R has also been shown to selectively block efaroxan-induced insulin secretion.
More Information Supplier PageKU14R is an antagonist of the pancreatic ??-cell atypical imidazoline binding site (putative I3 receptor). KU14R has also been shown to selectively block efaroxan-induced insulin secretion.
More Information Supplier Page
